Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer-Reference-Cited by-同舟云学术

Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer

Published:2017-08-10 Issue:13 Volume:18 Page:1357-1362
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Conte Benedetta¹,Poggio Francesca¹,Del Mastro Lucia²^ORCID

Affiliation:

1. Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino - IST , Genova, Italy

2. Department of Medical Oncology, U.O. Sviluppo Terapie Innovative, IRCCS AOU San Martino - IST , Genova, Italy

Funder

Associazione Italiana per la Ricerca sul Cancro

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2017.1363181

Reference29 articles.

1. Surveillance , Epidemiology and end results (SEER). [cited 2017 April 1]. Available from: http://www.seer.cancer.gov.

2. Occurrence of breast cancer subtypes in adolescent and young adult women

3. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

4. American Society of Clinical Oncology Endorsement of the Cancer Care Ontario Practice Guideline on Adjuvant Ovarian Ablation in the Treatment of Premenopausal Women With Early-Stage Invasive Breast Cancer

5. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fine-Tuning Adjuvant Endocrine Therapy for Early-Stage Breast Cancer: An Expert Consensus on Open Issues for Future Research;Clinical Cancer Research;2023-11-28

2. Obesity and Breast Cancer: Interaction or Interference with the Response to Therapy?;Current Oncology;2023-01-16

3. The prognostic significance of serum interferon-gamma (IFN-γ) in hormonally dependent breast cancer;Cytokine;2022-04

4. The significance of HOXB7 and IL17RB serum levels in prognosis of hormonally dependent breast cancer: A pilot study;Advances in Medical Sciences;2021-09

5. Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial;Journal of Clinical Oncology;2019-02-10